Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Arezzo – page 59

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Arezzo at a glance
1 011
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 011 trials in Arezzo

Open in trial search

Chronic myeloid leukaemia

Not recruiting

Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Farma S.p.A.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Polycythaemia vera+10

Not recruiting

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Panobinostat
  • Sponsor:Novartis Pharma Services AG

Colorectal cancer metastatic

Not recruiting

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Colorectal cancer metastatic+1

Not recruiting

Study on the Safety and Effectiveness of Trifluridine/Tipiracil, Capecitabine, and Bevacizumab for Patients with Metastatic Colorectal Cancer Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Non-small cell lung cancer

Not recruiting

Study of Chemotherapy with Osimertinib in Non-Small Cell Lung Cancer Patients Who Have Progressed After Initial Osimertinib Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Acute myeloid leukaemia+2

Not recruiting

Study on Continued Treatment with Sabatolimab for Adults with High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Unfit for Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

  • Bladder Cancer Immunotherapy
  • Urothelial Carcinoma Treatment
  • BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

  • Castration-resistant Disease
  • Targeted Molecular Therapies
  • Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

  • Immunotherapy Combinations
  • Targeted Molecular Agents
  • Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.